ANX005 is a humanized anti-C1q monoclonal antibody administered intravenously. ANX005 inhibits C1q function as the initiating molecule of the classical complement cascade, and, as a result, inhibits the entire classical pathway, but leaves the lectin and alternative pathways intact . ANX005 has been shown to be effective in several preclinical models of disease.
ANX007 has the same C1q inhibition properties as ANX005 and is designed for treatment of ophthalmic diseases such as glaucoma and geographic atrophy (an advanced form of age-related macular degeneration with no approved treatments). Local administration enables target engagement within the eye while leaving the complement pathway to function elsewhere in the body.
Annexon is also advancing other therapeutics that modulate multiple targets in the early complement cascade.